Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.
The Lancet ( IF 168.9 ) Pub Date : 2017-11-01 , DOI: 10.1016/s2213-2600(17)30387-9
Richard J Allen ₁ , Joanne Porte ₂ , Rebecca Braybrooke ₃ , Carlos Flores ₄ , Tasha E Fingerlin ₅ , Justin M Oldham ₆ , Beatriz Guillen-Guio ₇ , Shwu-Fan Ma ₈ , Tsukasa Okamoto ₉ , Alison E John ₁₀ , Ma'en Obeidat ₁₁ , Ivana V Yang ₁₂ , Amanda Henry ₁₀ , Richard B Hubbard ₃ , Vidya Navaratnam ₃ , Gauri Saini ₁₀ , Norma Thompson ₁₀ , Helen L Booth ₁₃ , Simon P Hart ₁₄ , Mike R Hill ₁₅ , Nik Hirani ₁₆ , Toby M Maher ₁₇ , Robin J McAnulty ₁₈ , Ann B Millar ₁₉ , Philip L Molyneaux ₁₇ , Helen Parfrey ₂₀ , Doris M Rassl ₂₁ , Moira K B Whyte ₁₆ , William A Fahy ₂₂ , Richard P Marshall ₂₂ , Eunice Oballa ₂₂ , Yohan Bossé ₂₃ , David C Nickle ₂₄ , Don D Sin ₂₅ , Wim Timens ₂₆ , Nick Shrine ₁ , Ian Sayers ₁₀ , Ian P Hall ₁₀ , Imre Noth ₈ , David A Schwartz ₂₇ , Martin D Tobin ₂₈ , Louise V Wain ₂₈ , R Gisli Jenkins ₂

Affiliation

Department of Health Sciences, University of Leicester, Leicester, UK.
Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK; Nottingham Molecular Pathology Node, University of Nottingham, Nottingham, UK.
National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
Research Unit, Hospital Universitario NS de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Spain; Instituto Tecnológico y de Energías Renovables (ITER, S.A.), Santa Cruz de Tenerife, Spain.
Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA; Department of Biostatistics and Informatics, University of Colorado, Denver, CO, USA.
Department of Internal Medicine, University of California Davis, Davis, CA, USA.
Research Unit, Hospital Universitario NS de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.
Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA.
Department of Medicine, University of Colorado Denver, Denver, CO, USA.
Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals, Nottingham, UK.
The University of British Columbia Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.
Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA; Department of Medicine, University of Colorado Denver, Denver, CO, USA.
Department of Thoracic Medicine, University College London Hospitals, London, UK.
Respiratory Research Group, Centre for Cardiovascular and Metabolic Research, The Hull York Medical School, Hull, UK.
Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
MRC Centre for Inflammation Research at the University of Edinburgh, Edinburgh, UK.
NIHR Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK; Fibrosis Research Group, Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London, UK.
UCL Respiratory Centre for Inflammation and Tissue Repair, University College London, London, UK.
Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK.
Respiratory Medicine, Papworth Hospital, Cambridge, UK.
Department of Pathology, Papworth Hospital, Cambridge, UK.
Fibrosis Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Department of Molecular Medicine, Laval University, Quebec City, QC, Canada.
Merck Research Laboratories, Genetics and Pharmacogenomics, Boston, MA, USA.
The University of British Columbia Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada; Respiratory Division, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Department of Pathology and Medical Biology, University Medical Centre Groningen, Groningen Research Institute for Asthma and COPD, University of Groningen, Groningen, Netherlands.
Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA; Department of Medicine, University of Colorado Denver, Denver, CO, USA; Department of Immunology, University of Colorado Denver, Denver, CO, USA.
Department of Health Sciences, University of Leicester, Leicester, UK; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK.

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain cause, and few treatment options. Studies have identified a significant genetic risk associated with the development of IPF; however, mechanisms by which genetic risk factors promote IPF remain unclear. We aimed to identify genetic variants associated with IPF susceptibility and provide mechanistic insight using gene and protein expression analyses.

中文翻译：

与欧洲血统人群特发性肺纤维化易感性相关的遗传变异：一项全基因组关联研究。

特发性肺纤维化（IPF）是一种慢性进行性肺部疾病，死亡率高，病因不明，治疗选择少。研究已经确定了与 IPF 的发展相关的重大遗传风险；然而，遗传风险因素促进 IPF 的机制仍不清楚。我们旨在确定与 IPF 易感性相关的遗传变异，并使用基因和蛋白质表达分析提供机制洞察力。

更新日期：2017-10-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>